Currently, more than 100 000 patients undergo BMT annually worldwide, a number that is steadily increasing. Long-term survival after BMT has improved significantly since its inception over 40 years ago, owing to improved supportive care and early recognition of long-term complications. With broadening indications, more options for BMT and improvement in survival, by 2020 there may be up to a million long-term survivors after BMT, globally.
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Higher than average rates of second malignancies, cardiopulmonary, infectious, endocrine and renal diseases, and bone loss or avascular necrosis within this population suggest that the rapidly swelling ranks of BMT survivors require more frequent screening and earlier interventions than the general population.
The purpose of Blood and Marrow Transplantation Long-Term Management is to describe practical approaches for screening and managing these late effects, with the goal of reducing preventable morbidity and mortality associated with BMT.
The book is split into 37 chapters from a large number of expert contributors in their corresponding fields encompassing all aspects of late effects after transplantation including, but not limited to, organ-specific complications, infectious complications, and health-and quality-of-life-related issues.
Three indices are included in the book; one related to 'NMDP/Be the Match posttransplant guidelines', the second is regarding long-term follow-up calendar and the third is related to commonly used transplant-related medications in long-term survivors.
This new book is the first to address the needs of the increasing population of long-term survivors after SCT, making it an important resource for all oncologists, hematologists and primary-care physicians involved in the long-term management and care of BMT patients.
The book is available in print and electronic versions as well as for download and through smart electronic devices.
